Neil Edward O'COnnell

Neil Edward O'COnnell

Auto-generated profile, based on publicly available information

Neil Edward O'COnnell

Centre for Health and Wellbeing Across the Lifecourse, Department of Health Sciences, Brunel University London, Uxbridge, United Kingdom

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in The Journal of Pain
Verified
Journal Article
Closed access
KBK. Jane Bowering
K. Jane Bowering
NONeil E. O'COnnell
Neil E. O'COnnell
ATAbby Tabor
Abby Tabor
MCMark J. Catley
Mark J. Catley
HLHayley Leake
Hayley Leake
TSTasha Stanton
Tasha Stanton

17 October 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NONeil E O'Connell
Neil E O'Connell
JCJohn Cossar
John Cossar
LMLouise Marston
Louise Marston
BWBenedict M Wand
Benedict M Wand
DBDavid Bunce
David Bunce
LSLorraine H De Souza
Lorraine H De Souza
Many double-blind clinical trials of transcranial direct current stimulation (tDCS) use stimulus intensities of 2 mA despite the fact that blinding has not been formally validated under these conditions. The aim of this study was to test the assumption that sham 2 mA tDCS achieves effective blinding. A randomised double blind crossover trial. 100 tDCS-naïve healthy volunteers were incorrectly advised that they there were taking part in a trial of tDCS on word memory. Participants attended for two separate sessions. In each session, they completed a word memory task, then received active or sham tDCS (order randomised) at 2 mA stimulation intensity for 20 minutes and then repeated the word memory task. They then judged whether they believed they had received active stimulation and rated their confidence in that judgement. The blinded assessor noted when red marks were observed at the electrode sites post-stimulation. tDCS at 2 mA was not effectively blinded. That is, participants correctly judged the stimulation condition greater than would be expected to by chance at both the first session (kappa level of agreement (κ) 0.28, 95% confidence interval (CI) 0.09 to 0.47 p = 0.005) and the second session (κ = 0.77, 95%CI 0.64 to 0.90), p = <0.001) indicating inadequate participant blinding. Redness at the reference electrode site was noticeable following active stimulation more than sham stimulation (session one, κ = 0.512, 95%CI 0.363 to 0.66, p<0.001; session two, κ = 0.677, 95%CI 0.534 to 0.82) indicating inadequate assessor blinding. Our results suggest that blinding in studies using tDCS at intensities of 2 mA is inadequate. Positive results from such studies should be interpreted with caution.

1 August 2013 in The Journal of Pain
Verified
Journal Article
Closed access
MCMark J. Catley
Mark J. Catley
NONeil E. O'COnnell
Neil E. O'COnnell
GMG. Lorimer Moseley
G. Lorimer Moseley

13 April 2018 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
NONeil E O'COnnell
Neil E O'COnnell
LMLouise Marston
Louise Marston
SSSally Spencer
Sally Spencer
LDLorraine H DeSouza
Lorraine H DeSouza
BWBenedict M Wand
Benedict M Wand
Background This is an updated version of the original Cochrane Review published in 2010, Issue 9, and last updated in 2014, Issue 4. Non‐invasive brain stimulation techniques aim to induce an electrical stimulation of the brain in an attempt to reduce chronic pain by directly altering brain activity. They include repetitive transcranial magnetic stimulation (rTMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), transcranial random noise stimulation (tRNS) and reduced impedance non‐invasive cortical electrostimulation (RINCE). Objectives To evaluate the efficacy of non‐invasive cortical stimulation techniques in the treatment of chronic pain. Search methods For this update we searched CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, LILACS and clinical trials registers from July 2013 to October 2017. Selection criteria Randomised and quasi‐randomised studies of rTMS, CES, tDCS, RINCE and tRNS if they employed a sham stimulation control group, recruited patients over the age of 18 years with pain of three months' duration or more, and measured pain as an outcome. Outcomes of interest were pain intensity measured using visual analogue scales or numerical rating scales, disability, quality of life and adverse events. Data collection and analysis Two review authors independently extracted and verified data. Where possible we entered data into meta‐analyses, excluding studies judged as high risk of bias. We used the GRADE system to assess the quality of evidence for core comparisons, and created three 'Summary of findings' tables. Main results We included an additional 38 trials (involving 1225 randomised participants) in this update, making a total of 94 trials in the review (involving 2983 randomised participants). This update included a total of 42 rTMS studies, 11 CES, 36 tDCS, two RINCE and two tRNS. One study evaluated both rTMS and tDCS. We judged only four studies as low risk of bias across all key criteria. Using the GRADE criteria we judged the quality of evidence for each outcome, and for all comparisons as low or very low; in large part this was due to issues of blinding and of precision. rTMS Meta‐analysis of rTMS studies versus sham for pain intensity at short‐term follow‐up (0 to < 1 week postintervention), (27 studies, involving 655 participants), demonstrated a small effect with heterogeneity (standardised mean difference (SMD) ‐0.22, 95% confidence interval (CI) ‐0.29 to ‐0.16, low‐quality evidence). This equates to a 7% (95% CI 5% to 9%) reduction in pain, or a 0.40 (95% CI 0.53 to 0.32) point reduction on a 0 to 10 pain intensity scale, which does not meet the minimum clinically important difference threshold of 15% or greater. Pre‐specified subgroup analyses did not find a difference between low‐frequency stimulation (low‐quality evidence) and rTMS applied to the prefrontal cortex compared to sham for reducing pain intensity at short‐term follow‐up (very low‐quality evidence). High‐frequency stimulation of the motor cortex in single‐dose studies was associated with a small short‐term reduction in pain intensity at short‐term follow‐up (low‐quality evidence, pooled n = 249, SMD ‐0.38 95% CI ‐0.49 to ‐0.27). This equates to a 12% (95% CI 9% to 16%) reduction in pain, or a 0.77 (95% CI 0.55 to 0.99) point change on a 0 to 10 pain intensity scale, which does not achieve the minimum clinically important difference threshold of 15% or greater. The results from multiple‐dose studies were heterogeneous and there was no evidence of an effect in this subgroup (very low‐quality evidence). We did not find evidence that rTMS improved disability. Meta‐analysis of studies of rTMS versus sham for quality of life (measured using the Fibromyalgia Impact Questionnaire (FIQ) at short‐term follow‐up demonstrated a positive effect (MD ‐10.80 95% CI ‐15.04 to ‐6.55, low‐quality evidence). CES For CES (five studies, 270 participants) we found no evidence of a difference between active stimulation and sham (SMD ‐0.24, 95% CI ‐0.48 to 0.01, low‐quality evidence) for pain intensity. We found no evidence relating to the effectiveness of CES on disability. One study (36 participants) of CES versus sham for quality of life (measured using the FIQ) at short‐term follow‐up demonstrated a positive effect (MD ‐25.05 95% CI ‐37.82 to ‐12.28, very low‐quality evidence). tDCS Analysis of tDCS studies (27 studies, 747 participants) showed heterogeneity and a difference between active and sham stimulation (SMD ‐0.43 95% CI ‐0.63 to ‐0.22, very low‐quality evidence) for pain intensity. This equates to a reduction of 0.82 (95% CI 0.42 to 1.2) points, or a percentage change of 17% (95% CI 9% to 25%) of the control group outcome. This point estimate meets our threshold for a minimum clinically important difference, though the lower confidence interval is substantially below that threshold. We found evidence of small study bias in the tDCS analyses. We did not find evidence that tDCS improved disability. Meta‐analysis of studies of tDCS versus sham for quality of life (measured using different scales across studies) at short‐term follow‐up demonstrated a positive effect (SMD 0.66 95% CI 0.21 to 1.11, low‐quality evidence). Adverse events All forms of non‐invasive brain stimulation and sham stimulation appear to be frequently associated with minor or transient side effects and there were two reported incidences of seizure, both related to the active rTMS intervention in the included studies. However many studies did not adequately report adverse events. Authors' conclusions There is very low‐quality evidence that single doses of...

1 December 2016 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Open access
NONeil E. O'COnnell
Neil E. O'COnnell
CCChad E. Cook
Chad E. Cook
BWBenedict M. Wand
Benedict M. Wand
SWStephen P. Ward
Stephen P. Ward
Given the scale and cost of the low back pain problem, it is imperative that healthcare professionals involved in the care of people with low back pain have access to up-to-date, evidence-based information to assist them in treatment decision-making. Clinical guidelines exist to promote the consistent best practice, to reduce unwarranted variation and to reduce the use of low-value interventions in patient care. Recent decades have witnessed the publication of a number of such guidelines. In this narrative review, we consider three selected international interdisciplinary guidelines for the management of low back pain. Guideline development methods, consistent recommendations and inconsistencies between these guidelines are critically discussed.

30 April 2013 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
NONeil E O'COnnell
Neil E O'COnnell
BWBenedict M Wand
Benedict M Wand
JMJames H McAuley
James H McAuley
LMLouise Marston
Louise Marston
GMG Lorimer Moseley
G Lorimer Moseley